Alzheimer’s Disease (AD) is a multifactorial progressive neurodegenerative disorder
characterized by memory loss, disorientation, and gradual deterioration of intellectual capacity.
Its etiology has not been elucidated yet. To date, only one therapeutic approach has
been approved for the treatment of AD. The pharmacotherapy of AD has relied on noncompetitive
N-methyl-D-aspartate (NMDA) receptor antagonist - memantine, and acetylcholinesterase
(AChE) inhibitors (AChEIs) - tacrine, donepezil, rivastigmine and galantamine.
Donepezil was able to ameliorate the symptoms related to AD mainly via AChE, but also
through reduction of β-amyloid burden. This review presents the overview of donepezilrelated
compounds as potential anti-AD drugs developed on the basis of cholinergic hypothesis
to act as solely AChE and butyrylcholinesterase (BChE) inhibitors.
Keywords: Alzheimer’s disease, acetylcholinesterase, butyrylcholinesterase, donepezil, inhibitor, treatment,
Rights & PermissionsPrintExport